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Abstract: N-type voltage-dependent Ca2+ channels (CaV2.2) are located at nerve endings in 
the central and peripheral nervous systems and are strongly associated with the pathological 
processes of cerebral ischemia and neuropathic pain. CaV2.2 blockers such as the ω-
conotoxin MVIIA (Prialt) are analgesic and have opioid-sparing effects. With the aim to 
develop new multi-target analgesic compounds, we designed the first ω-conotoxin/opioid 
peptidomimetics based on the enkephalin-like sequence Tyr-D-Ala-Gly-Phe (for the opioid 
portion) and two fragments derived from the loop-2 pharmacophore of ω-conotoxin MVIIA. 
Antinociceptive activity evaluated in vitro and in vivo revealed differential affinity for CaV2.2 
and opioid receptors and no significant synergistic activity.  
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Pharmacological management of severe and chronic pain is still a challenging task. Currently 
available analgesic drugs are not always efficacious, and pain control remains a large unmet 
therapeutic need.(1) Opioids are considered the standard of analgesic care for severe pain, but 
they have significant limitations in the management of neuropathic and chronic pain at 
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tolerable doses. Chronic opioid therapy is often connected to undesired side-effects like 
dyschezia, vomiting, drowsiness and hypoventilation, resulting in a poor quality life for 
patients.(2)  
 
Recently, regulatory agencies in the Unites States of America and Europe approved 
ziconotide (Prialt) for treatment of severe neuropathic pain. This complex peptide, the 
synthetic analogue of ω-conotoxin MVIIA which is produced by the cone snail Conus magus, 
acts by blocking the Ca2+ flow mediated by N-type Ca2+ channels or CaV2.2 at the level of the 
spinal cord. This inhibition results in the suppression of neurotransmitter release in ascending 
key pain pathway, to mediate analgesia.(3) 
 
Importantly, ziconotide has opioid-sparing effects and provides superior pain relief compared 
to opioids alone,(4) although serious side-effects restrict its use to a subset of chronic 
neuropathic pain sufferers that are refractory to opioids.(5) 
 
Despite the high potency and selectivity for CaV2.2, and its well established role as pain 
regulator in humans, ziconotide is not an ideal drug due to its peptidic nature, large size, 3D 
structural complexity (three disulphide bridges), toxicity and administration route. 
 
To overcome these limitations, over the last decade, several research groups have focused on 
developing small molecules with CaV2.2 blocking activity.(6) The ω-conotoxin 
pharmacophore incorporates a two-point binding model including the hydroxyl group of 
residue Tyr13 and the amino group of residue Lys2,(7) and was later extended to include 
additional residues including Arg10 and Leu11.(8) Development of novel small molecules that 
mimic the functional amino acids present in loop 2 of ω-conotoxin includes dendroids by 
Menzler ad co-workers,(6b) linear ligands developed by Parke-Davis and cyclic peptides 
developed at the University of Queensland by the Lewis Group (Figure 1).(9)  
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Figure 1: Relevant structural analogies between native ω-conotoxin loop-two (MVIIA), other ω-conotoxin 
analogues (Parke-Davis 1,4, Univ. of Queensland I) and our novel mono-functional ω-conotoxin analogues 3 
and 4 (namely: Mollica I and Mollica II).(6b,9) 
 
Interestingly, a synergistic analgesic effect is achieved by intrathecal (i.th.) administration of 
ziconotide with opioids showing a cooperative analgesic effect, accompanied by reduced 
development of dependence and tolerance. Pain control achieved by co-administration of 
morphine and Ziconotide is higher than that obtained by using one of these drugs alone.(10) 
This suggests that compounds with multi-target pharmacology, in particular molecules 
combining opioid agonist and a CaV2.2 inhibitor pharmacophores may provide superior pain 
relief while reducing the incidence of side effects (Table 1). 
 
Thus, following the recent literature on bivalent ligands (11) and on the adjacent 
pharmacophores concept recently developed by Hruby,(12) and Ballet,(13) we report two 
novel multi-target analogues 1 and 2 (Figure 2) as starting point to design a new class of 
bivalent compounds with potent antinociceptive effects in acute and chronic pain.  
 
For the design of multi-target peptides 1 and 2, the well known opioid portion represented by 
the enkephalin-like opioid motif H-Tyr-D-Ala-Gly-Phe (YaGF) (14) was used. This sequence 
was chosen because it has been previously used in the design of dimeric enkephalins (H-Tyr-
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D-Ala-Gly-Phe-NH-)2,(15) DADLE (YaGPl) (16) and other bivalent ligands.(17) YaGF was 
linked through its C-terminus to the N-terminus of the ω-conotoxin pharmacophores 3 and 4 
(Table 1).  
 
Conversely, development of a short and effective ω-conotoxin pharmacophore was 
challenging. In the design of the conotoxin portion of peptides 1-4, we took into account the 
numerous and diverse ω-conotoxin SAR published in the last two decades. Initially we 
selected two small linear peptides derived directly from the native sequence of ω-conotoxin 
loop-2: H-Ser-Arg-Leu-Met-Tyr-NH2 (3) and H-Lys-Ser-Arg-Leu-Met-Tyr-NH2 (4) namely 
Mollica I and Mollica II respectively, depicted in Figure 1. 
 
3 is the natural linear amino acid sequence loop-2 of the ω-conotoxin MVIIA,(18) which has 
been further simplified to obtain the short sequence Arg-Leu-Tyr. Both sequences were used 
in the design of the bivalent peptides 1 and 2. As depicted in Figure 1, the Arg-Leu-Tyr motif 
is frequently present in other highly active ω-conotoxin-analogues.  
 
It was also hypothesized that an additional cationic centre, as in the analogue ‘Queensland I’ 
(Figure 1), could further enhance the binding affinity of the linear residue. Thus, the sequence 
H-Lys-Ser-Arg-Leu-Met-Tyr-NH2 (4) was also tested for CaV2.2 blocking activity.(8,19) All 
results of the in vitro tests for the bivalent peptides 1 and 2 and the mono-functional 
compounds YaGF, 3 and 4 are shown in Tables 2 and 3. Compounds 1 and 2 preserved a 
good opioid activity but showed only a micromolar range functionality for VGGC blocking 
activity. Peptides 3 and 4 showed the same range of activity to N-Type-VGCC. All 
compounds where also tested by in vivo nociception tests (Figures 3 and 4).  
 
 
 
Figure 2: Design of bivalent compounds 1 and 2. 
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Table 1; Structures, data analysis of peptides 1-4. 
Name Products MW ESI-MS HPLC-RT 
(min)a 
1 H-Tyr-D-Ala-Gly-Phe-Ser-Arg-Leu-Met-Tyr-
NH2  
1105.5 1106.3 7.68 
2 H-Tyr-D-Ala-Gly-Phe-Arg-Leu-Tyr-NH2  888.0 889.2 5.35 
Mollica I (3) H-Ser-Arg-Leu-Met-Tyr-NH2  667.8 668.9 7.66 
Mollica II 
(4) 
H-Lys-Ser-Arg-Leu-Met-Tyr-NH2  795.9 796.8 7.47 
a
 HPLC chromatograms were recorded by a Kromasil 100-5C18 column (4.5 mm x 250 mm / 5 μm); flow 
rate = 0.8 mL/min; eluent: linear gradient of H2O/CH3CN, 0.1% trifluoroacetic acid, starting from 10% to 
60% CH3CN in 15 min. The MS data were recorded by a LCQ (Thermo Finnigan) ion trap mass 
spectrometer equipped with an electrospray ionization source (ESI). The fluid was nebulized by using N2 
sheath and auxiliary gas. Capillary temperature: 300 °C, spray voltage: 4.25 kV. 
 
Methods and Material 
Chemistry  
The bifunctional derivatives 1-2 and mono-functional conotoxin fragments 3-4 were 
synthesized on solid phase (SPPS), following standard Fmoc-strategy by using TBTU/HOBt 
for coupling reactions and piperidine 20% solution in DMF for Fmoc group deprotection as 
previously described.(20) Boc group for Lysine, Pbf for Arginine and tBu for Tyrosine and 
Serine were used as orthogonal protection groups. For detailed experimental procedures see 
Supporting Information. 
 
Biological evaluation 
The biological activity of compounds 1-4 was assessed in a range of in vitro assays, including 
μ, δ and κ receptor binding assays, G-protein stimulation assay in rat brain membranes and 
functional Cav2.2 assay. Mouse in vivo analgesic efficacy testing was also performed on 
peptides 1 and 2.(6c,21) For detailed experimental procedures see Supporting Information. 
 
Table 2: Cav2.2 and opioid receptors affinity of peptides 1-4 and reference compounds. 
Compounds 
 Receptor binding Kia (nM)  Cav2.2-mediated responses 
 µ  δ  κ  EC50a,c (μM) 
Controlb  0.36 ± 0.1  1.5 ± 0.3 5.9 ± 1.6 -- 
1  14.8 ± 4.8  22 ± 4.4  5.5 ± 1.5  93 ± 30 
2 
 
9.64 ± 2.4 
 
37.4 ± 7.4 
 226.5 ± 57.3  72 ± 37 
3  >1000  >1000 >1000 80 ± 6 
4  >1000  >1000 >1000 > 100 
Ziconotided  --  --  --  0.055 nM 
YaGF-NH2e  2.8  300 -- -- 
a ± S.E.M.; b the control was the appropriate opioid receptor specific ligand (µ, DAMGO; δ, 
Ile5,6 deltorphin II; κ, U69593); c EC50 values were calculated from the dose–response graphics; 
each data point was done in triplicate; d Ref. (22) and Ref. (17a). 
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Results and Discussion 
In vitro binding affinity 
In vitro assessment of bivalent peptides 1 and 2 and the mono-functional compounds YaGF, 
3 and 4 are shown in Tables 2 and 3. Compounds 1 and 2 maintained affinity at δ and μ 
opioid receptors compared with the native opioid tetrapeptide YaGP-NH2, (20a) with only a 
moderate decrease of the μ opiate receptor affinity and improved affinity (~ 10-fold) at the δ 
affinity.  
 
Table 3: GTP binding assays of compounds 1 and 2. 
Cpd 
 1  2 
 Emaxa  
(%) 
LogEC50a 
(EC50)b 
 Emaxa  
(%) 
LogEC50a 
(EC50)b 
Controlc 
 
186 ± 4 −5.97 ± 0.07 (1.06) 
 
179 ± 5 -6.26 ± 0.13 (0.54) 
+Cyp 
 
146 ± 6 −5.62 ± 0.18 (2.38) 
 
140 ± 4 -6.19 ± 0.21  (0.65) 
+nor-BNI 
 
158 ± 9 −5.52 ± 0.17 (3.05) 122± 4 -5.91 ± 0.34  (1.23) 
+NTI 
 
117 ± 8 −5.89 ± 0.67 (1.29) 117 ± 2 
-6.53 ± 0.29  
(0.29) 
a ± S.E.M.; b μM; c The control were peptides 1-2 in absence of 
specific antagonist opioids receptor, (Cyp, Cyprodime, μ selective; 
nor-BNI, Norbinaltorphimine, κ selective; NTI, Naltrindole, δ 
selective). 
 
Assessment of G-protein activation by peptides 1 and 2 towards opioid receptors was also 
performed. We applied the functional [35S]GTPγS binding assays on rat brain membrane 
preparations using the specific opioid receptor antagonists for comparison. Compounds 1 and 
2 stimulated G-protein activation, indicating that these two hybrid peptides were agonists at 
opioid receptors (Table 3), consistent with results from opioid receptor binding studies (Table 
2). 
 
All molecules 1-4 were tested for the CaV2.2 assay. In contrast to native ω-conotoxins, 
compounds 1–4 exhibited weak or no functional activity at CaV2.2, with EC50 values in the 
micromolar range (Table 2). Peptide 4 showed the weakest blocking activity for CaV2.2, 
indicating that the addition of a Lys in position one did not enhance activity. 
 
These results suggest that conservation of the three-dimensional structure of the 
pharmacophore residues is critical for activity at CaV2.2, although a peptidomimetic with 
similar structure (Parke-Davis 4) was recently reported to possess nanomolar activity at 
CaV2.2 (Fig. 1). 
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In vivo assays 
To investigate how the different pharmacological properties of compounds 1-4 affected their 
analgesic profile, the in vivo formalin and tail flick tests were performed on all compounds. 
Results are shown in Figure 3 and Figure 4.  
 
 
 
Figure 3: Antinociceptive activity (formalin test) of ziconotide (Z, 0.1 nmol), DAMGO (D, 0.1 
nmol) peptides 1-4 (5 nmol) and Vehicle (V) after i.th. administration in mice (n = 10). The 
analgesic effects are evidenced by decreased licking (seconds, mean ± S.E.M.) quantified from 0 
to 10 min (early phase) and from 15 to 40 min (late phase) following formalin injection. 
Statistical significance was defined as P <0.05 (**P <0.05, *** P <0.001 vs vehicle). 
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Figure 4: Time-response of the analgesic activity (Tail Flick test) of ziconotide (0.1 nmol), DAMGO (0.1 
nmol) and compounds 1-4 (5 nmol) after i.th. administration in rats (n = 8). The activity is reported as 
percentage of the maximum possible effect (% M.P.E.) ± S.E.M. Statistical significance was assumed at P<0.05 
(**P<0.05; ***P<0.001).  
 
Both the in vivo formalin and tail flick data confirm that bivalent compounds 1-2 have a 
higher analgesic activity than monovalent ziconotide fragments 3 and 4, which are almost 
inactive at the concentration range of the tests. Overall, the activity of peptides 1-4 in terms 
of potency and efficacy was modest to weak and correlated well with activity at opioid 
receptors. 
 
Conclusion 
Previous studies indicate that bi-functional analgesic compounds can reverse neuropathic 
pain in a pain models and demonstrated some ability to cross the blood-brain barrier (BBB), 
in specific cases even with suppression of tolerance or addiction (i.e. mixed opioid-NK1 
antagonist Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-3’,5’-Bn-(CF3)2] and opioid-CCK Tyr-
DNle-Gly-Trp-Nle-Asp-Phe-NH2) (12,23) validating our hypothesis that a single drug with 
opioid pharmacophore/CaV2.2 blocker activity could be very effective for pain treatment. 
This work represents the first attempt to investigate the potential of multi-target compounds 
combining opioid agonist and CaV2.2 inhibitor pharmacophores (Table 1). The 
pharmacological profile of such compounds would be expected to combine potent analgesic 
efficacy in acute and neuropathic pain states and reduce the extent of tolerance. 
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Additional advantages over a multi-drug combinations might also include: (i) simpler 
administration; (ii) improved pharmacokinetic properties; (iii) reduced drug-drug interactions 
and (iv) better tissue targeting (because of significant anatomical overlap between VGCCs 
and opioid receptors in the CNS),.(12,13) 
 
The data obtained in this study show that our bivalent molecules (1 and 2) bind and activate μ 
and δ opioid receptors in nanomolar range, but bind CaV2.2 with µM affinity. Compounds 3 
and 4, which were designed as small ω-conotoxin fragments and had no activity at opioid 
receptors, had little or no analgesic efficacy. In contrast, the bivalent derivatives 1 and 2, 
which maintained good activity at opioid receptors effectively reversed pain behaviours in 
both the formalin and tail flick nociceptive assays despite relatively weak activity at CaV2.2. 
We conclude that the antinociceptive activity observed in the in vivo tests are likely explained 
by the opioid receptor activation evidence for a synergistic effect was not obtained. Although 
it has been previously demonstrated that properties of opioid peptides could be readily 
transposed to small multi-target ligands,(12,16,23) incorporation of more potent CaV2.2 
activity is more challenging. Further investigations are presently underway in our laboratory 
to develop bivalent molecules with more potent activity at Cav2.2.  
 
Supporting Information 
Synthetic procedures, characterization data for novel compounds and the biological methods 
used for in vitro/in vivo bio-assays are provided in the Supporting Information File. 
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